1,720,975 research outputs found
Indium-111 Oxine Platelets Survival In Patients Suffering Of Cardiac And Cerebral Arteriosclerosis
No full textNon lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response
No full textEffects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis.
Get PDFObjective: The aim of the study is to evaluate the effect of moderate Sicilian red wine consumption on cardiovascular risk factors and, in particular, on some inflammatory biomarkers.
Methods: A total of 48 subjects of both sexes who were nondrinkers or rare drinkers of moderate red wine were selected randomly subdivided into two groups assigned to receive with a crossover design a Sicilian red wine (Nero d’Avola or Torrepalino) during meals: Group A (n 24), in whom the diet was supplemented for 4 weeks with 250 ml/day of red followed by 4 weeks when they returned to their usual wine intake; and Group B (n 24), in whom the usual wine intake maintained for 4 weeks, followed by 4 weeks when the diet was supplemented with 250 ml/day of red wine. The following values measured in all tests: blood glucose, total and HDL-cholesterol and triglycerides, LDL-cholesterol, LDL/HDL apolipoproteins A1 and B, Lp(a), plasma C-reactive protein, TGFb1, D-Dimer, Factor VII , PAI Ag, t-PA Ag, fibrinogen, oxidized LDL Ab, total plasma antioxidant capacity.
Results: At the end of the red wine intake period, LDL/HDL, fibrinogen, factor VII, plasma C-reactive protein and oxidized Ab were significantly decreased, while HDL-C, Apo A1,TGFb1, t-PA, PAI and total plasma antioxidant capacity were significantly increased.
Conclusions: Our results show a positive effect of two Sicilian red wines on many risk factors and on some inflammatory biomarkers, suggesting that a moderate consumption of red wine in the adult population is a positive component of Mediterranean diet
[Evaluation of blood viscosity and erythrocyte filterability in chronic ischemic heart disease].
No full textEffect of moderate Sicilian red wines comsuption on inflammatory biomarkers of atherosclerosis
No full textOne-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease
No full textAim. Statins are the drugs of choice in heterozygous familial hypercholesterolemia (FH), which has a high risk of premature cardiovascular events including myocardial infarction, stroke, and surgical revascularization. Methods. A 1-year open-label study was conducted to test the efficacy and tolerability of Atorvastatin titrated to the target, in proven FH patients and to evaluate certain inflammatory parameters. One hundred and two FH patients (44 men and 58 women; mean age 58.7±3.6 years) were included in the study. After evaluation using the B-mode duplex scanning system of extracranial carotid arteries, the patients were divided into groups: Group 1 (15 men, 25 women) with carotid plaques or intima-media thickness (IMT) greater than 0.95 mm and Group 2 (30 men, 32 women) without carotid plaques or IMT less than 0.95 mm. After a 6-week hypolipemic diet phase all the patients were treated with atorvastatin titrated to achieve a low density lipoprotein (LDL-C) <100 mg/dL. Patients with carotid lesions were also submitted to an oral fixed dose of aspirin 100 mg/day. Results. In patients without and with carotid lesions, atorvastatin treatment (mean dosage: 23.5 mg/day) reduced triglycerides by 8.7% (P<0.005) and 10.6% (P<0.005), total cholesterol by 41.5% (P<0.005) and 42.6% (P<0.005), LDL-C by 55.8% (P<0.005) and 57.3% (P<0.005) and apolipoprotein B by 38.3% (P<0.005) and 37.2% (P<0.005) respectively, and increased the mean levels of high density lipoprotein cholesterol (HDL-C) by 8.7% (P<0.005) and 11% (P<0.005), and apolipoprotein A-I by 3.2% (P<0.05) and 3.3%, respectively. In both groups of patients the mean decrease (52 weeks) of fibrinogen was 19.8% (P<0.005) and 10.4% (P<0.005), respectively and of high sensitivity C-reactive protein (hs-CRP), 36.2% (P<0.005) and 38.2% (P<0.005), respectively. No variation of the parameters of safety and clinical tolerability of the drugs administered was observed. No variation in hematocrit in the patients taking ASA treatment was observed. Conclusion. In FH patients, 1-year atorvastatin treatment titrated to the target (LDL-C <100 mg/dL) was well tolerated and improved serum lipid levels and inflammatory parameters
Haemostatic and fibrinolytic abnormalities in obese patients and in patients with type 2 diabetes with metabolic syndrome
No full textOne year atorvastatin treatment in patients with familial hypercholesterolemia: effects on CRP and fibrinogen
No full text
Efficacia della associazione Atorvastatina e n-3 PUFA in pazienti affetti da dislipidemia combinata e ad alto rischio di eventi cardiovascolari
No full text- …
